Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Neurocrine Biosciences, Inc. (NASDAQ: NBIX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the twenty-two research firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation, sixteen have given a buy recommendation and one has